Tomoshi Tsuchiya

Dr. Tomoshi Tsuchiya


Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 November 2012 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
YMYutaka Maeda
Yutaka Maeda
Tomoshi TsuchiyaTomoshi Tsuchiya
Tomoshi Tsuchiya
HHHaiping Hao
Haiping Hao
DTDavid H. Tompkins
David H. Tompkins
YXYan Xu
Yan Xu
JWJeffrey A. Whitsett
Jeffrey A. Whitsett
Mucinous adenocarcinoma of the lung is a subtype of highly invasive pulmonary tumors and is associated with decreased or absent expression of the transcription factor NK2 homeobox 1 (NKX2-1; also known as TTF-1). Here, we show that haploinsufficiency of Nkx2-1 in combination with oncogenic KrasG12D, but not with oncogenic EGFRL858R, caused pulmonary tumors in transgenic mice that were phenotypically similar to human mucinous adenocarcinomas. Gene expression patterns distinguished tumor goblet (mucous) cells from nontumorigenic airway and intestinal goblet cells. Expression of NKX2-1 inhibited urethane and oncogenic KrasG12D-induced tumorigenesis in vivo. Haploinsufficiency of Nkx2-1 enhanced KrasG12D-mediated tumor progression, but reduced EGFRL858R-mediated progression. Genome-wide analysis of gene expression demonstrated that a set of genes induced in mucinous tumors was shared with genes induced in a nontumorigenic chronic lung disease, while a distinct subset of genes was specific to mucinous tumors. ChIP with massively parallel DNA sequencing identified a direct association of NKX2-1 with the genes induced in mucinous tumors. NKX2-1 associated with the AP-1 binding element as well as the canonical NKX2-1 binding element. NKX2-1 inhibited both AP-1 activity and tumor colony formation in vitro. These data demonstrate that NKX2-1 functions in a context-dependent manner in lung tumorigenesis and inhibits KrasG12D-driven mucinous pulmonary adenocarcinoma.

15 January 2018 in Interactive CardioVascular and Thoracic Surgery
Verified
Journal Article
Open access
PDF file
DTDaisuke Taniguchi
Daisuke Taniguchi
KMKeitaro Matsumoto
Keitaro Matsumoto
Tomoshi TsuchiyaTomoshi Tsuchiya
Tomoshi Tsuchiya
RMRyusuke Machino
Ryusuke Machino
YTYosuke Takeoka
Yosuke Takeoka
TNTakeshi Nagayasu
Takeshi Nagayasu
Currently, most of the artificial airway organs still require scaffolds; however, such scaffolds exhibit several limitations. Alternatively, the use of an autologous artificial trachea without foreign materials and immunosuppressants may solve these issues and constitute a preferred tool. The rationale of this study was to develop a new scaffold-free approach for an artificial trachea using bio-3D printing technology. Here, we assessed the circumferential tracheal replacement using scaffold-free trachea-like grafts generated from isolated cells in an inbred animal model. Chondrocytes and mesenchymal stem cells were isolated from F344 rats. Rat lung microvessel endothelial cells were purchased. Our bio-3D printer generates spheroids consisting of several types of cells to create 3D structures. The bio-3D-printed artificial trachea from spheroids was matured in a bioreactor and transplanted into F344 rats as a tracheal graft under general anaesthesia. The mechanical strength of the artificial trachea was measured, and histological and immunohistochemical examinations were performed. Tracheal transplantation was performed in 9 rats, which were followed up postoperatively for 23 days. The average tensile strength of artificial tracheas before transplantation was 526.3 ± 125.7 mN. The bio-3D-printed scaffold-free artificial trachea had sufficient strength to transplant into the trachea with silicone stents that were used to prevent collapse of the artificial trachea and to support the graft until sufficient blood supply was obtained. Chondrogenesis and vasculogenesis were observed histologically. The scaffold-free isogenic artificial tracheas produced by a bio-3D printer could be utilized as tracheal grafts in rats.

19 May 2004 in Physiological Genomics
Verified
Journal Article
Closed access
PDF file
Tomoshi TsuchiyaTomoshi Tsuchiya
Tomoshi Tsuchiya
JDJoseph M. Dhahbi
Joseph M. Dhahbi
XCXinping Cui
Xinping Cui
PMPatricia L. Mote
Patricia L. Mote
ABAndrzej Bartke
Andrzej Bartke
SSStephen R. Spindler
Stephen R. Spindler
Disrupted growth hormone/insulin-like growth factor-1 signaling (DF) and caloric restriction (CR) extend life span and delay the onset of age-related diseases in rodents. In combination, these interventions additively extend life span. To investigate the molecular basis for these effects, we performed genome-wide, microarray expression analysis of liver from homozygous and heterozygous Ames dwarf mice fed ad libitum or CR. CR and DF additively affected a group of 95 genes. Individually and together, DF and CR independently affected the expression of 212 and 77 genes, respectively. These results indicate that DF and CR affect overlapping sets of genes and additively affect a subset of genes. Together, the interventions produced changes in gene expression consistent with increased insulin, glucagon and catecholamine sensitivity, gluconeogenesis, protein turnover, lipid β-oxidation, apoptosis, and xenobiotic and oxidant metabolism; and decreased cell proliferation, lipid and cholesterol synthesis, and chaperone expression. These data suggest that the additive effects of DF and CR on life span develop from their additive effects on the level of expression of some genes and from their independent effects on other genes. These results provide a novel and focused group of genes closely associated with the regulation of life span in mammals.

2 March 2017 in EMBO Molecular Medicine
Verified
Journal Article
Open access
PDF file
MGMinzhe Guo
Minzhe Guo
KTkoichi tomoshige
koichi tomoshige
MMMichael Meister
Michael Meister
TMThomas Muley
Thomas Muley
TFTakuya Fukazawa
Takuya Fukazawa
YMYutaka Maeda
Yutaka Maeda
Though invasive mucinous adenocarcinoma of the lung (IMA) is pathologically distinctive, the molecular mechanism driving IMA is not well understood, which hampers efforts to identify therapeutic targets. Here, by analyzing gene expression profiles of human and mouse IMA, we identified a Mucinous Lung Tumor Signature of 143 genes, which was unexpectedly enriched in mucin‐producing gastrointestinal, pancreatic, and breast cancers. The signature genes included transcription factors FOXA3, SPDEF, HNF4A, mucins MUC5AC, MUC5B, MUC3, and an inhibitory immune checkpoint VTCN1 / B7‐H4 (but not PD‐L1 / B7‐H1 ). Importantly, induction of FOXA3 or SPDEF along with mutant KRAS in lung epithelium was sufficient to develop benign or malignant mucinous lung tumors, respectively, in transgenic mice. FOXA3 and SPDEF induced MUC5AC and MUC5B, while HNF4A induced MUC3 in human mucinous lung cancer cells harboring a KRAS mutation. ChIP‐seq combined with CRISPR/Cas9 determined that upstream enhancer regions of the mucin genes MUC5AC and MUC5B , which were bound by SPDEF, were required for the expression of the mucin genes. Here, we report the molecular signature and gene regulatory network driving mucinous lung tumors.

1 August 2012 in Lung Cancer
Verified
Journal Article
Closed access
JAJunichi Arai
Junichi Arai
Tomoshi TsuchiyaTomoshi Tsuchiya
Tomoshi Tsuchiya
MOMasahiro Oikawa
Masahiro Oikawa
KMKoji Mochinaga
Koji Mochinaga
THTomayoshi Hayashi
Tomayoshi Hayashi
TNTakeshi Nagayasu
Takeshi Nagayasu

1 June 2007 in Lung Cancer
Verified
Journal Article
Closed access
Tomoshi TsuchiyaTomoshi Tsuchiya
Tomoshi Tsuchiya
SAShinji Akamine
Shinji Akamine
MMMasashi Muraoka
Masashi Muraoka
RKRyotaro Kamohara
Ryotaro Kamohara
KTKoichi Tsuji
Koichi Tsuji
NYNaoya Yamasaki
Naoya Yamasaki